Highest-materiality recent filing
Rocket One forms strategic AI partnership with Placeve for defense, space, edge computing
Rocket One made an initial investment in Placeve; no dollar amount disclosed.
Rocket One regains Nasdaq minimum bid price compliance
Nasdaq confirmed compliance with Listing Rule 5550(a)(2) on June 24, 2026.
Rocket One appoints Major General Malcolm Frost (Ret.) to Advisory Board
Major General Frost brings 31 years of U.S. Army leadership; served as Chief of Public Affairs and Deputy Director for Operations at NMCC.
Rocket One raises ATM offering capacity by $6.83M; $9.28M already sold under agreement
Rocket One increased ATM offering cap by $6.83M; H.C. Wainwright acts as agent.
Dr. Bandyopadhyay is a Commonwealth Professor at Virginia Commonwealth University and nanomagnetics/spintronics authority.
Rocket One accepted into AMD AI Developer Program for nanomagnetic AI accelerator simulation
Accepted into AMD AI Developer Program, gaining access to AI cloud resources, technical training, and developer tools.
Hoth Therapeutics renames to Rocket One Inc.; ticker changes to RKTO, pivots to space AI chip tech
Name change effective May 26, 2026; new ticker RKTO starts trading on Nasdaq May 28, 2026.
Hoth Therapeutics to restructure as Rocket One, entering AI chip licensing deal with VCU
Exclusive licenses from VCU for nanomagnetic matrix multiplier (AI acceleration) and spintronic memory for defense/space.
Hoth Therapeutics forms Rocket One subsidiary for space industry assets
Formed wholly-owned subsidiary Rocket One Inc. to enter space industry.
Hoth Therapeutics receives Nasdaq deficiency notice for minimum bid price non-compliance
Nasdaq notified Hoth on April 30, 2026 that bid price closed below $1.00 for 30 consecutive business days (Mar 18 – Apr 29).
Hoth Therapeutics resumes ATM equity offering under existing H.C. Wainwright agreement
On April 16, 2026, Hoth filed a new prospectus supplement to resume sales of common stock under its ATM agreement with H.C. Wainwright.
Hoth Therapeutics closes $2.0M registered direct offering of 2.86M shares at $0.70 plus warrants
Gross proceeds of ~$2.0M from sale of 2,857,144 shares at $0.70 each; used for working capital.
Prepared presentation for US government officials on weight loss drug HT-VA and broader therapeutics pipeline
Hoth Therapeutics updates corporate presentation with clinical milestones and cash position
HT-001 Phase 2a open-label cohort showed promising results; case study published Sept 2024.
Hoth Therapeutics expands crypto treasury to include Ethereum and Solana
Board approved up to $1M in Bitcoin, Ethereum, and/or Solana as treasury reserve asset.
Hoth Therapeutics enters new CEO employment agreement with $550k salary and 800k share grant
CEO Robb Knie's new employment agreement includes $550,000 annual base salary and up to $550,000 annual bonus.
All five director nominees (Knie, Sarnoff, Linsley, Pavell, Camarra) re-elected with strong support.
Hoth Therapeutics reports 100% efficacy in Phase 2a of HT-001 for EGFRI skin toxicities
Phase 2a CLEER-001 study: 100% of patients achieved primary endpoint; 66% reported reduced pain/itching.
Hoth Therapeutics regains Nasdaq minimum bid price compliance after 10-day closing above $1.00
Received Nasdaq notice on June 18, 2025 confirming compliance with Listing Rule 5550(a)(2) after 10 consecutive business days at or above $1.00.
Hoth Therapeutics updates pipeline timelines, reports cash runway and share count in corporate deck
Cash on hand sufficient to fund all clinical and preclinical programs in development.
Hoth Therapeutics receives Nasdaq delisting notice for bid price below $1.00
Closing bid price of common stock below $1.00 for 30 consecutive business days ending May 12, 2025.
Hoth subsidiary's PCT patent application for hair loss treatment fee-confirmed
Merveille.ai received USPTO confirmation that PCT/US2025/022598 fees were paid in full.
Mean pruritus score dropped 50% from 1.6 to 0.8 by Day 21 in open-label portion of CLEER-001 Phase 2a trial.
Hoth restates 2023, 2024 financials for prepaid R&D errors; initiates HT-KIT toxicity study
Restatement: prepaid expenses understated by $722,765 at Dec 31, 2023; R&D expenses understated by $260,732 for FY2023.
Hoth Therapeutics increases ATM offering capacity by $5M to $7.7M total
Increased maximum aggregate offering under ATM facility with H.C. Wainwright by $5M.
Hoth Therapeutics regains Nasdaq compliance on minimum bid price requirement
Received Nasdaq notice on Jan 23, 2025 that stock closed at or above $1.00 for 10 consecutive business days (Jan 7-22, 2025).
Hoth Therapeutics releases December 2024 corporate presentation highlighting pipeline and milestones
HT-001 Phase 2a for EGFR inhibitor skin toxicity: all sites active, enrolling open-label and double-blind; interim PK data expected Q1 2025.
Hoth Therapeutics board approves up to $1M in Bitcoin as treasury reserve asset
Board authorized purchase of up to $1 million in Bitcoin as a treasury reserve asset.
Hoth Therapeutics enters into $2.7M ATM offering with H.C. Wainwright
ATM facility to sell up to $2.7M of common stock on Nasdaq through H.C. Wainwright as sales manager.
Hoth Therapeutics receives Nasdaq deficiency notice for minimum bid price non-compliance
Nasdaq notified HOTH on Oct 30, 2024 that common stock failed minimum $1.00 bid price for 30 consecutive business days.
Hoth Therapeutics shareholders re-elect board, ratify auditor, approve equity plan increase
All five incumbent directors re-elected; vote totals ranged from 637,415 to 700,399 for each.
Hoth Therapeutics board amends bylaws to clarify shareholder voting entitlement
Board approved Amendment No. 2 to Amended and Restated Bylaws on June 14, 2024.
Hoth Therapeutics raises $4.2M via warrant exercise inducement, issues new warrants for 3.75M shares
Gross proceeds of ~$4.2M from immediate cash exercise of 2.5M existing warrants at reduced exercise price of $1.6775 (down from $5.00).
Hoth Therapeutics files patent for weight loss therapeutic and side effect mitigation
Filed a patent application with USPTO on January 8, 2024 for a therapeutic targeting obesity and side effects of weight loss drugs.
Filed Articles of Incorporation in Nevada for merveille.ai on October 4, 2023.
Hoth Therapeutics raises $2.89M via 1.1M shares and warrants at $2.63/share
Gross proceeds ~$2.89M from sale of 1,100,000 shares (or equivalents) and concurrent private placement of warrants.
All five nominees (Robb Knie, David Sarnoff, Graig Springer, Wayne Linsley, Jeff Pavell) elected to board with large majority of votes cast.
Hoth Therapeutics files investor presentation materials; content not available in provided text
Filed presentation materials for use in meetings starting August 16, 2023.
Hoth Therapeutics sets Aug 18, 2023 annual meeting; shareholder deadlines June 16 and June 23.
Board set 2023 annual meeting for August 18, 2023.
FDA completed safety review and permitted IND for HT-001 to treat rash and skin disorders from EGFR inhibitor therapy.
Hoth Therapeutics raises $10M in private placement of shares and warrants at $5.00 per unit
Gross proceeds of $10M from sale of 2M shares (or equivalents) and warrants for 2.5M shares at $5.00 per unit.
Board expanded to five members; Dr. Jeff Pavell appointed Dec 7, 2022, and joins compensation committee.
Hoth Therapeutics regains Nasdaq minimum bid price compliance; delisting risk removed
Received Nasdaq notice on Nov 9, 2022, confirming compliance with $1.00 minimum bid price rule.
Hoth Therapeutics issues 2M shares of Series B Preferred with 10-to-1 voting for $1,000
Sold 2,000,000 Series B Preferred shares to a single investor for aggregate $1,000; shares have $0.0001 par value.
Reverse stock split at 1:25 ratio becomes effective pre-market on October 26, 2022.
Board approved amendment reducing quorum for shareholder meetings from majority to one-third of outstanding voting stock.
Hoth Therapeutics files presentation materials for Alzheimer's Association International Conference
Company prepared presentation materials for use starting July 18, 2022, including at the Alzheimer's Association International Conference (July 31 – Aug 4, 2022).
Hoth Therapeutics receives Nasdaq extension to Dec 26, 2022 to meet $1 bid price rule
Received Nasdaq extension to regain compliance with minimum bid price, now deadline Dec 26, 2022.
Hoth Therapeutics shareholders reject reverse stock split; Nasdaq compliance at risk
Shareholders re-elected directors Robb Knie, David Sarnoff, Graig Springer, Wayne Linsley.
Hoth Therapeutics releases presentation materials for BIO International Convention
Presentation materials filed as Exhibit 99.1 for use at BIO International Convention June 13-16, 2022.
On April 9, 2025, Graig Springer informed Hoth Therapeutics, Inc. (the “Company”) that he will be resigning from the Company’s Board of Directors (the “Board”) as well as the Company’s audit committee, compensation committee and nominating and corporate governance committee effective as of April 15, 2025.
On December 12, 2022, Dr. Johns joined the Company’s Scientific Advisory Board and will continue to consult and monitor the Company’s pipeline development in such role.
On December 7, 2022, the board of directors (the “Board”) of Hoth Therapeutics, Inc. (the “Company”) increased the size of the Board to five members and appointed Jeff Pavell, D.O., as a member of the Board to fill the vacancy created by the increase in the size of the Board.
On December 9, 2022 (the “Separation Date”), the employment of Stefanie Johns as Chief Scientific Officer of the Company ceased.
On January 19, 2022, Vadim Mats informed Hoth Therapeutics, Inc. (the “Company”) that he will be resigning from the Company’s Board of Directors (the “Board”) as well as the Company’s compensation committee and nominating and corporate governance committee effective as of January 31, 2022.
Max materiality 0.85 · Median 0.55 · Most common event other_material